Overview

Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)

Status:
Terminated
Trial end date:
2014-06-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Tocilizumab is a safe and effective treatment for steroid-refractory acute graft versus host disease.
Phase:
Phase 2
Details
Lead Sponsor:
Weill Medical College of Cornell University
Treatments:
Glucocorticoids